Compare PRDO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRDO | HRMY |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 1997 | 2020 |
| Metric | PRDO | HRMY |
|---|---|---|
| Price | $34.16 | $32.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $42.00 | ★ $44.11 |
| AVG Volume (30 Days) | 605.4K | ★ 650.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 10.50 | 7.97 |
| EPS | ★ 0.85 | 0.55 |
| Revenue | $581,296,000.00 | ★ $868,453,000.00 |
| Revenue This Year | $4.28 | $19.75 |
| Revenue Next Year | $2.89 | $12.88 |
| P/E Ratio | ★ $40.32 | $58.55 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $26.66 | $25.52 |
| 52 Week High | $38.50 | $40.87 |
| Indicator | PRDO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 57.58 |
| Support Level | $34.13 | $31.61 |
| Resistance Level | $35.35 | $33.11 |
| Average True Range (ATR) | 0.89 | 0.90 |
| MACD | 0.10 | 0.15 |
| Stochastic Oscillator | 69.81 | 74.43 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the its revenue comes from the Colorado Technical University segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.